Fluphenazine

phenothiazine, piperazine side chain, high D2 potency

Also sold as Prolixin, Modecate.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Fluphenazine has no classical nutrient-depletion machinery documented in its own FDA labeling or in the drug-specific literature located for this review. It is not described as inducing or inhibiting CYP450 enzymes; it undergoes extensive hepatic first-pass metabolism (oral bioavailability of roughly 2.7%), is converted in part to fluphenazine sulfoxide via CYP2D6, and is excreted via both urine and feces. No chelation, gastric-pH, mucosal-injury, or renal-tubular-wasting mechanism for any classical vitamin or mineral is documented for this drug. That absence is itself the first finding, not a gap to paper over.

phenothiazine, piperazine side chain, high D2 potency · ATC N05AB02 (WHO ATC/DDD Index) · also sold as Prolixin and Modecate · reviewed 2026-10-02. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Fluphenazine in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Sodium / water balance - SIADH-pattern dilutional hyponatremia

Yellow — Low

Evidence in: Tier B

Two independent, fluphenazine-specific 1975 case reports describe SIADH-pattern dilutional hyponatremia. This is a water-retention disturbance, not a sodium or any nutrient deficiency, and supplementation is not the remedy.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. yellow · tier B · excess/retention

Limits on what this shows

Null/negative findings: No population-incidence study specific to fluphenazine was located to quantify frequency.
At-risk subgroups: Patients with comorbid psychogenic polydipsia (a recognized, illness-intrinsic risk in chronic schizophrenia, independent of drug - confounding by indication is not excluded here); elderly patients on concurrent diuretics or SSRIs.

Regulatory status

Not addressed in current FDA labeling for either formulation (no SIADH/hyponatremia warning located in the label text retrieved).

Population evidence

De Rivera 1975, Ann Intern Med 82:811-812, and Zuniga & Hazan 1975, Ann Intern Med 83:735-737 - two separate single-patient case reports of inappropriate ADH secretion temporally associated with fluphenazine therapy. Two independent Tier B drug-specific sources, consistent direction; no Tier A clinical-cohort confirmation located, which caps the grade at yellow.

Mechanism

Proposed central dopaminergic/serotonergic potentiation of ADH release, a recognized FGA-class phenomenon.

Counter-evidence held on record

This is a dilutional/retention risk, not depletion. Sodium or fluid supplementation is not indicated and would be hazardous; the clinically correct response to hyponatremia here is fluid restriction and prescriber reassessment, never added salt or water intake.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

Evidence in: Tier B

Fluphenazine directly increases superoxide formation via mitochondrial Complex I in ex vivo human and bovine tissue, independent of any nutrient cofactor - a direct pharmacologic effect on the organelle, not a cofactor-deficiency mechanism.

Full detail and limits

Limits on what this shows

Null/negative findings: Effect was not significant in every tissue tested; no human clinical mitochondrial-function study (lactate/pyruvate ratio, muscle biopsy, etc.) in fluphenazine-treated patients was located.
At-risk subgroups: None clinically defined. Theoretical concern with high cumulative dose / long-term depot use, given fluphenazine's large volume of distribution (~298 L) and extensive tissue uptake.

Regulatory status

Not addressed in FDA labeling for either fluphenazine formulation; no mitochondrial-toxicity warning on file.

Population evidence

Ex vivo bovine heart mitochondrial membranes and human liver/heart tissue homogenates (Elexpe et al. 2022, Biomedicines 10(5):980). Fluphenazine raised superoxide production via NADH dehydrogenase (Complex I), Emax 36.8% in bovine heart membranes, described as "similar to rotenone, but with lower potency." Effect was significant in human liver and heart homogenates but tissue-variable elsewhere. Design is in vitro/ex vivo, not a clinical cohort - Tier B.

Mechanism

Direct Complex-I-site redox interference, consistent with phenothiazines' known membrane-partitioning behavior; not mediated by any vitamin or mineral cofactor.

Counter-evidence held on record

This is ex vivo enzyme/membrane data, not a diagnosed human mitochondrial disease or a measured nutrient deficiency. No supplement (e.g. CoQ10, L-carnitine) is recommended on this basis; no functional marker has been shown to move in fluphenazine-treated patients. See Overlap map: this source is shared with the Oxidative stress entry below and must not be counted as two independent confirmations.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

Evidence in: Tier B

Three independent fluphenazine-specific animal/ex vivo studies, spanning rat liver, kidney, and brain and human/bovine tissue, consistently show increased oxidative-damage markers; no fluphenazine-stratified human clinical antioxidant-status study exists to raise this above yellow.

Full detail and limits

Limits on what this shows

Null/negative findings: None of the three studies reported a null result; the limitation is design, not direction - all are animal/ex vivo, none is a human clinical cohort.
At-risk subgroups: None established in humans.
Counter-evidence: A human study of plasma MDA across first- and second-generation antipsychotics found elevated oxidative stress with first-generation agents (haloperidol, flupentixol) versus several second-generation agents, but its cohort excluded fluphenazine entirely - Tier C context only, not counted toward this entry's tier, and flagged because flupentixol/haloperidol are not phenothiazines.

Regulatory status

Not addressed in FDA labeling.

Population evidence

(1) Corte et al. 2009, Basic Clin Pharmacol Toxicol : chronic fluphenazine in rats increased lipid peroxidation in liver and kidney homogenates; co-administered diphenyl diselenide partially normalized antioxidant enzyme activity. (2) Schaffer et al. 2016, Neurochem Res 41(5):1170-1184: fluphenazine 25 mg/kg i.m. in rats altered catalase activity and raised ROS in cortex and striatum, alongside orofacial dyskinesia; a co-administered herbal antioxidant attenuated both the behavioral and oxidative endpoints. (3) Elexpe et al. 2022 (as above): increased superoxide formation in human/bovine tissue ex vivo. All three are drug-specific, animal or ex vivo - Tier B.

Mechanism

Overlaps with the Mitochondrial burden entry (Complex I-linked superoxide generation) plus broader tissue-level antioxidant-enzyme disturbance (catalase, lipid peroxidation) independent of dietary antioxidant intake.

Counter-evidence held on record

Animal and ex vivo oxidative-stress findings are not the same as a diagnosed human antioxidant deficiency. No antioxidant supplement dose is recommended; any such use should be discussed with the prescriber given fluphenazine's own narrow margins (QT, hepatic, hematologic).

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

Evidence: tier C · excess/retention · class extrapolation

Serum copper was significantly elevated, not depleted, in a schizophrenia case-control cohort that included a small subgroup on unnamed depot neuroleptics; fluphenazine decanoate is a plausible but unconfirmed member of that subgroup, so this is a bounded, excess-direction, class-level signal, not a fluphenazine-specific finding.

Full detail and limits

Limits on what this shows

Null/negative findings: Whole-cohort elevation could equally reflect the underlying illness (confounding by indication, Hard Rule 6) rather than any specific drug or drug class; the study cannot separate these.
At-risk subgroups: None defined.
Counter-evidence: No fluphenazine-specific copper study was located after a multi-channel search (WebSearch, Crossref, Europe PMC, Semantic Scholar); see access notes under Sources.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Herrán et al. 2000, Psychiatry Research 94:51-58. Case-control study, 62 schizophrenia outpatients vs. matched controls; 17 of the 62 were on depot neuroleptics (individual agents not named in the abstract retrieved). Serum copper: 117.4 ± 23.4 µg/dL (patients) vs. 105.6 ± 27.9 µg/dL (controls), significantly higher in patients. Tier C for fluphenazine specifically - the drug is not individually named, and the depot subgroup is small.

Mechanism

Copper is a cofactor for dopamine-β-hydroxylase and ceruloplasmin; study authors hypothesize treatment-related accumulation rather than an illness-intrinsic effect, but this is not proven by the design used (no drug-naive arm).

Counter-evidence held on record

This is an excess/retention-direction signal, not depletion. It does not support copper supplementation under any circumstance; if anything, it flags copper as a nutrient to avoid over-supplementing in this population, not one to replace.

Iron

Yellow — Low

Evidence: tier C · cross-chemical-class extrapolation

A comparison study found iron-deficiency-pattern anemia with chronic haloperidol - a different chemical class (butyrophenone) from fluphenazine's phenothiazine class - but not with fluphenazine itself; this is labeled here as a pharmacological-class (high-potency, strongly D2-antagonist first-generation antipsychotic), not a chemical-class, extrapolation.

Full detail and limits

Limits on what this shows

Null/negative findings: Clozapine (a different class entirely) showed minimal iron-profile change in the same study, arguing against a universal antipsychotic-class effect.
At-risk subgroups: None defined for fluphenazine specifically.
Counter-evidence / context (not used for grading): Serum iron falls acutely and severely (≥2 SD below normal in ~96% of episodes in one 26-episode case series) during neuroleptic malignant syndrome (NMS), a rare idiosyncratic reaction associated with high-potency FGAs including fluphenazine (a fluphenazine-specific NMS case report exists: Aruna & Murungi 2005). This acute drop is framed by its authors as an acute-phase-reaction marker of the NMS episode itself, not a chronic nutrient-depletion mechanism of fluphenazine. Per Hard Rule 2, NMS is the drug's own adverse-reaction outcome; the iron drop that accompanies it is disclosed here purely as a clarification so it is never mistaken for a depletion claim, and it is not used as grading evidence for this entry.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Wasti, Zahid & Ahmed 2013, Int J Adv Res 1(10):111-118. Cross-sectional study, 120 schizophrenia patients (92 on haloperidol, 28 on clozapine) vs. 44 controls. Haloperidol group showed a significant (p<0.0001) drop in hemoglobin, RBC count, packed cell volume, and serum iron/ferritin with raised TIBC; ~75% showed >10% hypochromic/microcytic cells. Clozapine group showed minimal change. No drug-naive baseline arm. Tier C for fluphenazine: haloperidol is chemically a butyrophenone, not a phenothiazine; it is presented here only as a defensible pharmacological-class member (high-potency typical antipsychotic), explicitly not as a same-chemical-class (phenothiazine) finding.

Mechanism

Study authors propose iron chelation at or near striatal D2 receptor sites affecting receptor sensitivity - speculative, and not confirmed for fluphenazine.

Counter-evidence held on record

No clinical trial has measured iron status in fluphenazine-treated patients specifically. This entry flags a plausible, class-adjacent hypothesis worth watching, not a basis for iron supplementation absent a confirmed lab deficiency.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No fluphenazine-specific or defensible class-level gut-microbiome evidence was found, and no circulating consumer claim ties fluphenazine or typical/first-generation antipsychotics to microbiome disruption.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

Why no grade: Dual condition met: (1) no Tier B/C evidence - the accessible antipsychotic-microbiome literature concentrates almost entirely on second-generation agents (olanzapine, risperidone, clozapine) studied for metabolic-syndrome mechanisms; first-generation/phenothiazine agents like fluphenazine are comparatively unstudied in this domain in what could be retrieved. (2) no circulating claim to rebut - no consumer-facing "fluphenazine disrupts your gut bacteria" claim was identified.

Channels tried

WebSearch, multiple phrasings ("fluphenazine gut microbiome composition antipsychotic," "phenothiazine typical first-generation antipsychotic gut microbiota") - returned only second-generation-antipsychotic results before this session's WebSearch budget was exhausted mid-category. Crossref REST API (query "fluphenazine gut microbiome," 233,195 raw hits; top-10 relevance-ranked results all irrelevant - a clean zero on relevance, not a block). Europe PMC REST API - blocked, HTTP 429, on 2 separate attempts at different points in this session. Semantic Scholar Graph API - blocked, HTTP 429/403, on 2 attempts. PubMed direct page fetch - blocked by reCAPTCHA/403 on every attempt this session. Google/Bing/DuckDuckGo direct fetch as a search fallback - blocked by robots.txt, unusable this session. DailyMed/FDA label - read in full; no microbiome content.

Assessment

Reads as a genuine literature gap (FGAs are simply less studied than SGAs for this endpoint) compounded by, but not fully explained by, this session's tooling limits on PubMed/Europe PMC/Semantic Scholar and an exhausted search budget. A revision should re-run those three channels once access is confirmed restored before treating this as settled.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production (pyruvate dehydrogenase complex)

Yellow — Low

Direction: reverse direction (as labelled in the source) · Evidence in: Tier B

In a head-to-head enzyme assay of eleven antipsychotics, fluphenazine was among the least potent inhibitors of the pyruvate dehydrogenase complex (PDHC), the gateway enzyme into the TCA cycle and ATP production - a comparatively favorable finding relative to its own chemical relatives chlorpromazine and thioridazine, not a depletion effect.

Full detail and limits

Limits on what this shows

Null/negative findings: In vitro enzyme assay only; no human clinical ATP, lactate, or pyruvate biomarker study in fluphenazine-treated patients was located.
At-risk subgroups: None defined; theoretical relevance only to patients with an independent PDHC-deficiency diagnosis, who are not represented in the psychiatric population this label addresses.

Regulatory status

Not addressed in FDA labeling.

Population evidence

Sacks, Esser & Sacks 1991, Biol Psychiatry 29:176-182. Bovine heart and rat brain PDHC preparations exposed to 11 antipsychotics including fluphenazine, chlorpromazine, thioridazine, and thiothixene. "Chlorpromazine and thioridazine inhibited [PDHC] the most and fluphenazine and thiothixene the least." Drug-specific, mechanistic in vitro enzyme assay - Tier B.

Mechanism

Direct interaction at the pyruvate dehydrogenase (PDH) component of the complex; authors link inhibition potency to likely benefit from adjunct thiamine/lipoic-acid-type ("A+T") therapy in a regional PDHC-deficiency model - a therapy not established or validated for ordinary fluphenazine use.

Counter-evidence held on record

This is a reverse-direction, relatively protective finding compared with other phenothiazines, not a deficiency signal, and must not be reworded as an ATP-depletion claim. It also does not license disregarding thiamine or lipoic acid status in a patient who has an independent indication for them.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No fluphenazine-specific or defensible phenothiazine-class evidence on hemoglobin, hematocrit, red-cell mass, methemoglobin, or tissue oxygen delivery was found, and no circulating claim alleges fluphenazine impairs oxygen delivery.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. ungraded

Limits on what this shows

Why no grade: Dual condition met: (1) no Tier B/C evidence located. Fluphenazine's own label documents leukopenia/agranulocytosis/thrombocytopenic and nonthrombocytopenic purpura/pancytopenia, but that is the drug's own labeled toxicity on blood-cell lines (an outcome), not a nutrient- or oxygen-carrying-capacity finding, and is excluded here under Hard Rule 2. (2) no circulating consumer claim about fluphenazine and oxygen delivery/hemoglobin function was identified.

Channels tried

WebSearch ("fluphenazine methemoglobinemia case report," "fluphenazine anemia hemoglobin hematocrit case report") - both queries returned only case reports on phenazopyridine, a similarly-named but unrelated drug (a name-collision false lead disclosed here so it is not mistaken for a true fluphenazine hit; no genuine fluphenazine-specific result surfaced). Crossref REST API (query "phenothiazine methemoglobinemia") - returned only generic reference-work entries (SpringerReference, a problem-based-learning chapter on benzocaine/lidocaine, a CABI "phenothiazine poisoning" compendium entry), none fluphenazine-specific or clearly a primary phenothiazine-antipsychotic study. Europe PMC REST API - blocked, HTTP 429, repeated attempts. PubMed direct fetch - blocked by reCAPTCHA/403. Google/Bing/DuckDuckGo direct fetch - blocked by robots.txt. DailyMed/FDA label - read in full; hematologic section addresses blood dyscrasias only, not oxygen-carrying capacity.

Assessment

Genuine gap versus tooling limitation cannot be fully disentangled here, because several discovery channels (Europe PMC, PubMed, general search-engine fallback) were unavailable for this entire category during this review. Flagged for re-check on revision once PubMed/Europe PMC access is confirmed restored.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

Calcium / Vitamin D ("antipsychotics deplete your vitamin D/calcium and cause bone loss")
Where it comes from: General antipsychotic-and-bone-health consumer and practitioner content links long-term antipsychotic treatment to reduced bone mineral density and reframes this as a vitamin D or calcium "depletion."
Why it fails: Fluphenazine's own FDA labeling names a different, well-characterized mechanism: antipsychotic treatment elevates prolactin, and "the elevation persists during chronic administration," producing galactorrhea, amenorrhea, gynecomastia, and impotence. It is this prolactin-driven secondary hypogonadism - not a vitamin D or calcium absorption/dietary deficiency - that is linked to reduced bone mineral density in the literature (Naidoo, Goff & Klibanski, Psychoneuroendocrinology 2003, a review, not individually stratified to fluphenazine). Per Hard Rule 2, low bone mineral density arising from the drug's own intended dopamine-blocking/prolactin-elevating pharmacology is an outcome, not a nutrient deficiency. No fluphenazine-specific study measuring 25-OH-vitamin D or dietary/serum calcium status was located.

How the body handles this medication

Metabolism: Extensive hepatic first-pass metabolism; oral bioavailability ~2.7%. Principal oxidative pathway is conversion to fluphenazine sulfoxide via CYP2D6. The FDA label itself does not name any CYP450 enzyme or describe induction/inhibition.FDA label [1,2]; secondary pharmacology compilation [3]
Elimination: Excreted via urine and feces; not cleared unchanged by the kidney. Oral hydrochloride half-life ~14-16 hours. The decanoate ester has a half-life of ~6.8-9.6 days, producing a depot effect with onset at 24-72 hours and symptom control for up to 4-6 weeks per injection.FDA decanoate label [2]; secondary pharmacology compilation [3]
Absorption / interactions: No food, mineral, or antacid interaction is described in FDA labeling. The only interaction warnings on file are pharmacodynamic: potentiation of CNS depressants and alcohol, and a caution against co-use with large doses of hypnotics.FDA label [1,2]
Hepatic / renal handling: Active liver damage is a contraindication. Renal function (BUN) is advised to be monitored during long-term therapy, with discontinuation if BUN becomes abnormal. No renal tubular electrolyte-wasting mechanism is described.FDA label [1,2]
Endocrine (labeled): "Neuroleptic drugs elevate prolactin levels; the elevation persists during chronic administration," with associated galactorrhea, amenorrhea, gynecomastia, and impotence. This is the labeled mechanism behind antipsychotic-associated bone-density change - see Fails verification.FDA label [2]
Hematologic (labeled): Leukopenia, neutropenia, agranulocytosis, thrombocytopenic and nonthrombocytopenic purpura, eosinophilia, and pancytopenia are documented class/drug risks. This is the drug's own labeled toxicity on blood-cell lines, not a nutrient-mediated finding (see Oxygen delivery/utilization, ungraded).FDA label [1,2]

What the research says is worth watching

General information from the medication label and the studies above. It is not personal medical advice, and any change belongs with your prescriber.

Hematology
CBC with differential
Baseline and periodically during therapy, given labeled agranulocytosis/leukopenia/pancytopenia risk. More urgent with fever or sore throat.
Electrolyte
Serum sodium
Check if polydipsia, confusion, or new-onset seizures develop, especially with concurrent SSRIs/diuretics or a history of psychogenic polydipsia. Two fluphenazine-specific SIADH case reports exist.
Hepatic
Liver function tests
Baseline and during the first months of therapy, per labeled cholestatic-jaundice risk.
Renal
BUN / renal function
Periodically during long-term therapy per label; discontinue fluphenazine if BUN becomes abnormal.
Endocrine / skeletal
Prolactin, and BMD if long-term
If menstrual irregularity, galactorrhea, or long-term high-potency FGA use is present. This is a hormonal work-up, distinct from a vitamin D/calcium deficiency work-up (see Fails verification).
Cardiac
ECG/QTc
Per the label's general caution on "altered electrocardiographic tracings" with phenothiazines.

Overlap map, to prevent double counting

Mitochondrial burden
Shares evidence with: Oxidative stress
Note: Both entries cite Elexpe et al. 2022 ( Biomedicines 10(5):980): the same ex vivo human/bovine-tissue experiment measured both Complex I-linked superoxide formation (oxidative stress endpoint) and the underlying Complex I interference (mitochondrial endpoint). Read as one independent line of evidence appearing in two entries, not two independent confirmations.
Iron
Shares evidence with: (context only, not a shared grading source)
Note: The NMS-associated acute serum-iron drop (Keck et al. 1991; a 26-episode case series) is cited inside the Iron entry only as a mechanism clarification, not as grading evidence, and does not overlap with any other graded entry in this dossier.

All references used above

Fluphenazine

Findings for this medication

What the research found

Sodium / water balance - SIADH-pattern dilutional hyponatremia

The five body-system areas

⚡Mitochondrial Burden

Mitochondrial burden

💥Oxidative Stress

Oxidative stress

⚖️Copper and Iron Balance

Copper

Iron

🌿Gut Microbiome Risk

Gut microbiome risk

💨Oxygen and ATP Output

ATP production (pyruvate dehydrogenase complex)

Oxygen delivery/utilization

Claims checked and not supported

Calcium / Vitamin D ("antipsychotics deplete your vitamin D/calcium and cause bone loss")

How the body handles this medication

What the research says is worth watching

Overlap map, to prevent double counting

Mitochondrial Burden

Oxidative Stress

Copper and Iron Balance

Gut Microbiome Risk

Oxygen and ATP Output